Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
Cell>Point LLC
Study ID
NCT01899833
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Coronary Artery Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 99mTc-Sestamibi — DIAGNOSTIC_TEST
    An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.

Study Details

This study will compare how well a new radiolabeled imaging agent ECDG compares to the current testing for coronary artery disease (radiolabeled Sestamibi) during a rest and stress cardiac test as documented from results of a coronary angiogram (if performed).

Key Dates

Start date
May 10, 2025
Status verified
Mar 2025
Primary completion
Dec 31, 2025
Completion
Apr 30, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: 99mTc-EC-DG, Diagnostic
    99mTc-EC-DG (25 ± 5 mCi, up to 250 µg EC-DG) will be administered by intravenous (IV) bolus injection. Other Name:Technetium-99m-labeled Ethylenedicysteine-Deoxyglucose

Primary Outcome Measure

Efficacy: Characterization of the efficacy of 99mTCc-ECDG in the evaluation of Coronary Artery Disease [ Time Frame: Visit 1a through Visit 3 approximately 3 to 20 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Tom Hennebry, MDOklahoma CityOklahoma73210
Tom Hennebry, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Oklahoma City, OK

By research site
Tom Hennebry, MD· Oklahoma City, OK

Related Studies